Ironwood and Forest to Present Linaclotide Results from Phase 3 Trials in Patients with Irritable Bowel Syndrome with Constipation (IRWD, FRX)

Ironwood Pharmaceuticals, Inc. IRWD and Forest Laboratories, Inc. FRX today announced they will be presenting linaclotide results from Phase 3 clinical trials in patients with irritable bowel syndrome with constipation during the 2011 Digestive Disease Week annual meeting that will be held in Chicago from May 7 through May 10, 2011. Linaclotide is an investigational guanylate cyclase type-C agonist for the treatment of IBS-C and chronic constipation. Ironwood and Forest released top-line results from the two Phase 3 IBS-C trials late last year.